# An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

> **NCT06996652** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yale University** · enrollment: 108 (estimated)

## Conditions studied

- REM Sleep Behavior Disorder

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06996652
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06996652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06996652, "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06996652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*